CRP and melanoma: In melanoma where CRP impairs adaptive immunity, a study demonstrated that compared to CRP < 10 mg/L, CRP ≥ 10 mg/L conferred poorer overall survival in subjects with any stage, stage I/II, or stage III/IV disease, and worse disease-free survival for those with stage I/II disease.